Acute myeloid leukaemia refractory

6 trials 1 recruiting MedDRA PT
6 Registered trials
1 Recruiting
6 Unique sponsors
7 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
L Oncology (ATC L) 1
M Musculoskeletal (ATC M) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
BCL-2 inhibitor 1 substance
Phase I/II: 1 Phase I: 1 Phase I (First in Human): 4

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase I/II

1 trial
  • Aop Orphan Pharmaceuticals GmbH Commercial
    LB-208
    2025-523396-38-00 1 country n=60
    Pending

Phase I

1 trial
  • Celgene Corp. Commercial
    IMP not specified
    2022-500573-13-00 1 country 2021 n=22
    Ended

Phase I (First in Human)

4 trials
  • Aptose Biosciences Inc. Commercial
    IMP not specified
    2023-503244-14-00 4 countries 2023 n=103
    Ended
  • AstraZeneca AB Commercial
    AZD3632
    2025-521299-76-00 3 countries 2025 n=17
    Recruiting
  • Institut De Recherches Internationales Servier IRIS Commercial
    ALLOPURINOL; RASBURICASE; S227928; VENETOCLAX
    2024-514356-33-00 3 countries 2025 n=54
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    SAR-443579
    2023-508357-58-00 2 countries 2022 n=57
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Celgene Corp. Commercial 1 Phase I 0
Aptose Biosciences Inc. Commercial 1 Phase I (First in Human) 0
AstraZeneca AB Commercial 1 Phase I (First in Human) 1
Institut De Recherches Internationales Servier IRIS Commercial 1 Phase I (First in Human) 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase I (First in Human) 0
Aop Orphan Pharmaceuticals GmbH Commercial 1 Phase I/II 0
New trials by year
2021
1
2022
1
2023
1
2025
2
← All indication landscapes